1. Scrip
  2. >>New Products

US FDA Approval Of Novo Nordisk's Victoza For Young T2D Patients A Treatment Milestone

 
• By Sten Stovall

The new indication means Victoza is the first non-insulin drug approved to treat type 2 diabetes in young patients since metformin was approved for pediatric use in 2000. Victoza has been approved to treat adult patients with type 2 diabetes since 2010.

Blood sample
Move Gives Young T2D patients First New Treatment Option In Nearly 20 Years • Source: Shutterstock

Young patients aged 10-17 years in the US suffering from type 2 diabetes have a new treatment option after the US Food and Drug Administration approved of Novo Nordisk AS’s injectable therapy Victoza (liraglutide) as a means to lower their blood sugar, along with diet and exercise.

The expanded indication for Victoza, announced on 17 June, provides younger type 2 diabetics with a new medicine option beyond

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

Sustainability Key To ABL Bio’s Journey From ‘Good To Great’

 
• By Jung Won Shin

Helped by a recent major platform deal with GSK, South Korea's ABL Bio is aiming to build its R&D portfolio with an eye on being acquired in the future. CEO Sang Hoon Lee sat down with Scrip to explain the venture's journey so far and its ambitious roadmap.

Roche Reveals Another US Manufacturing Site As Tariff Pressures Seem To Ease

 
• By Mandy Jackson

Roche/Genentech unveiled plans for a $700m-plus manufacturing facility for weight loss drugs in North Carolina as President Trump signaled such investments could mean no tariffs for pharma.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.